S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Laser breakthrough could send stock soaring 2,467% (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Laser breakthrough could send stock soaring 2,467% (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Laser breakthrough could send stock soaring 2,467% (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Laser breakthrough could send stock soaring 2,467% (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
NASDAQ:ONTX

Onconova Therapeutics (ONTX) Stock Forecast, Price & News

$1.17
+0.03 (+2.63%)
(As of 05/31/2023 ET)
Compare
Today's Range
$1.11
$1.17
50-Day Range
$0.67
$1.42
52-Week Range
$0.62
$1.52
Volume
33,530 shs
Average Volume
456,148 shs
Market Capitalization
$24.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Onconova Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.73mentions of Onconova Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.21) to ($0.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.39 out of 5 stars

Medical Sector

900th out of 1,006 stocks

Pharmaceutical Preparations Industry

447th out of 492 stocks


ONTX stock logo

About Onconova Therapeutics (NASDAQ:ONTX) Stock

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Receive ONTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ONTX Stock News Headlines

“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
8-K: Onconova Therapeutics, Inc.
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Onconova Therapeutics (ONTX) Gets a Buy from Noble Financial
Q1 2023 Onconova Therapeutics Inc Earnings Call
Onconova Therapeutics (ONTX) to Release Earnings on Monday
Onconova Therapeutics (NASDAQ:ONTX) Upgraded at HC Wainwright
See More Headlines
Receive ONTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ONTX Company Calendar

Last Earnings
3/16/2023
Today
5/31/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONTX
Employees
14
Year Founded
N/A

Profitability

Net Income
$-18,960,000.00
Net Margins
-9,122.57%
Pretax Margin
-9,122.57%

Debt

Sales & Book Value

Annual Sales
$230,000.00
Book Value
$1.09 per share

Miscellaneous

Free Float
20,718,000
Market Cap
$24.53 million
Optionable
Not Optionable
Beta
1.78

Key Executives

  • Steven M. FruchtmanSteven M. Fruchtman
    President, Chief Executive Officer & Director
  • Mark P. Guerin
    Chief Operating & Financial Officer
  • Matthew Parris
    Vice President-Clinical Operations
  • Michael Saunders
    Chief Medical Officer
  • Adar Makovski Silverstein
    Senior Director & Head-Corporate Development













ONTX Stock - Frequently Asked Questions

Should I buy or sell Onconova Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ONTX shares.
View ONTX analyst ratings
or view top-rated stocks.

How have ONTX shares performed in 2023?

Onconova Therapeutics' stock was trading at $0.6457 at the start of the year. Since then, ONTX shares have increased by 81.2% and is now trading at $1.17.
View the best growth stocks for 2023 here
.

Are investors shorting Onconova Therapeutics?

Onconova Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 291,400 shares, a decline of 24.8% from the April 30th total of 387,400 shares. Based on an average daily volume of 540,800 shares, the days-to-cover ratio is currently 0.5 days.
View Onconova Therapeutics' Short Interest
.

When is Onconova Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ONTX earnings forecast
.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) released its quarterly earnings results on Thursday, March, 16th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.01. The biopharmaceutical company earned $0.06 million during the quarter, compared to the consensus estimate of $0.08 million. Onconova Therapeutics had a negative trailing twelve-month return on equity of 67.03% and a negative net margin of 9,122.57%.

When did Onconova Therapeutics' stock split?

Shares of Onconova Therapeutics reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.69%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Abraham N Oler, Abraham N Oler, E Premkumar Reddy, James J Marino, Mark Patrick Guerin and Steven M Fruchtman.
View institutional ownership trends
.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $1.17.

How much money does Onconova Therapeutics make?

Onconova Therapeutics (NASDAQ:ONTX) has a market capitalization of $24.53 million and generates $230,000.00 in revenue each year. The biopharmaceutical company earns $-18,960,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The official website for the company is www.onconova.com. The biopharmaceutical company can be reached via phone at (267) 759-3680, via email at ir@onconova.us, or via fax at 267-759-3681.

This page (NASDAQ:ONTX) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -